Developer docs
API playgroundTry for free, no card

Search company profiles

HUINNO

Full company profile

uuid0000z1y

Namestring
HUINNO
Legal namestring
주식회사 휴이노 (Huinno Co., Ltd.)
Websiteurl
huinno.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

HUINNO is a South Korea-based digital health company founded in 2014 that combines FDA-cleared wearable biosignal monitoring hardware with proprietary AI-based analytics to enable continuous cardiac monitoring and arrhythmia detection in both hospital and ambulatory settings. Its core platform comprises MEMO Cue, an in-hospital telemetry solution supporting up to 300 simultaneous patients via web-based monitoring on Cloud or On-Premise deployments, and MEMO Care, an ambulatory ECG monitoring solution extending continuous monitoring up to 14 days versus the standard 24-48 hour Holter window. Supporting hardware includes MEMO Patch M (FDA 510(k)-cleared, 12g, 8-day battery, defibrillation-protected), MEMO Patch 2 (IP27-rated, 14-day monitoring, iF and Red Dot Design Award winner), MEMO Band (MFDS-approved pulse oximeter), and MEMO Watch (CE-certified wrist-type multi-biosignal device). The proprietary MEMO AI engine powers bit-level deep-learning ECG segmentation and arrhythmia classification, ranked 1st globally in 4-lead and 6-lead categories at the PhysioNet AI Challenge 2021 and clinically validated at major Korean university hospitals with an 89% improvement in arrhythmia detection vs. traditional Holter monitoring.

The company operates a hybrid revenue model spanning hardware sales of wearable ECG devices to hospitals, SaaS subscriptions for MEMO Cue and MEMO Care monitoring platforms, and licensing/distribution arrangements including domestic Korean rights held by Yuhan Corporation and US market entry via Yuhan USA (announced March 2026). The recent acquisition of Korean National Health Insurance reimbursement code EX871 (March 2025) for remote heartbeat monitoring marks a transition toward recurring reimbursement-based revenue. HUINNO serves hospitals and cardiology departments as primary customers (H Plus Yangji Hospital being the first commercial MEMO Cue deployment covering ~100 beds), with secondary expansion targets including the US healthcare market and broader patient monitoring applications in general wards beyond ICU. The company has raised approximately $60M+ cumulatively across multiple funding rounds from 2019-2022, is backed by strategic investor Yuhan Corporation alongside financial investors including Smilegate Investment, Woori Venture Partners, and FuturePlay, and operates a subsidiary structure including wholly-owned Huinno AIM and the KHAIM joint venture with Korea University Medical Technology Holdings.

Short descriptiontext

HUINNO is a South Korea-based digital health company that combines FDA-cleared wearable ECG devices with AI-based arrhythmia detection algorithms to deliver continuous cardiac monitoring for hospitals and cardiology departments, serving both in-patient telemetry and ambulatory monitoring use cases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac monitoring software, wearable ECG devices, arrhythmia detection AI, remote patient monitoring, digital health platform
Industry6 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAQAF
Pulse Oximeters & Respiratory Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Monitoring Solutions
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Wearable Medical Device Sales
TypeHardware Sales
Description

Sales of wearable ECG monitoring devices including MEMO Patch M, MEMO Patch 2, and MEMO Watch. Devices are sold to hospitals and healthcare providers for patient monitoring.

huinno.com
2Software as a Service (SaaS) - Remote Patient Monitoring
TypeSubscription Recurring
Description

Cloud-based software subscriptions for MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring) platforms. The company received insurance reimbursement codes (보험수가) for remote heartbeat monitoring technology (EX871) in March 2025.

huinno.com
3Licensing and Distribution Agreements
TypeLicensing Royalties
Description

Licensing agreements for MEMO Patch domestic rights (Yuhan Corporation) and potential international distribution partnerships.

huinno.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1MEMO
Description

Digital health platform brand featuring products including MEMO Patch (wearable ECG monitoring device) and MEMO Care solutions.

huinno.com
Core offering1 text field

HUINNO develops and sells AI-powered cardiac monitoring solutions that combine wearable biosignal sensors with cloud-based AI analytics to enable continuous in-hospital patient monitoring (MEMO Cue) and extended ambulatory ECG monitoring (MEMO Care). The integrated stack includes FDA 510(k)-cleared and CE-certified wearable ECG/respiration devices (MEMO Patch M, MEMO Patch 2, MEMO Watch, MEMO Band), web-based central monitoring and ECG analysis software, and an award-winning arrhythmia detection algorithm, sold primarily to hospitals and cardiology departments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 89% higher arrhythmia detection rate compared to traditional 24-hour Holter monitoring
+4 more records
Product overview1 text field

HUINNO offers a dual-core product architecture centered on MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring), both powered by proprietary MEMO AI technology. The portfolio comprises two wearable ECG devices (MEMO Patch M for hospital monitoring, MEMO Patch 2 for extended ambulatory monitoring), supporting software platforms (MEMO Care Web for patient management, MEMO Report for ECG analysis, Medical Staff App for device control, MEMO for Desktop for data management), and mobile/portable solutions (MEMO Cue Mobile for hospital-wide monitoring). Recent additions include MEMO Band for oxygen saturation and MEMO Watch for multi-parameter vital signs. The system integrates with Samsung Galaxy devices and KakaoTalk chatbot for patient symptom tracking.

Product and service6 records
1MEMO Cue
CategoryIn-hospital cardiac telemetry
Description

In-hospital patient telemetry solution combining wearable ECG/respiration sensors (MEMO Patch M) with a web-based central monitoring software (MEMO Cue) and portable data transmission device (MEMO Cue Mobile), enabling 24-hour continuous cardiac monitoring beyond the ICU into general wards, multi-patient monitoring of up to 300 patients simultaneously, AI-based arrhythmia detection with 19 vital sign and 8 technical alarms, and Cloud or On-Premise deployment. Targeted at hospitals and healthcare systems for continuous inpatient cardiac monitoring.

2MEMO Care
CategoryAmbulatory ECG monitoring
Description

Ambulatory ECG monitoring solution using wearable devices (MEMO Patch 2) and big-data AI analysis to extend monitoring periods up to 14 days versus the 48-hour limit of standard Holter tests. Includes a web-based patient management system, ECG analysis and editing, automated report generation, and KakaoTalk chatbot integration for patient symptom and sleep logging. Targeted at cardiology departments and arrhythmia clinics for ambulatory arrhythmia diagnosis.

3MEMO Patch M
CategoryWearable ECG sensor
Description

Wearable ECG and respiration monitor for in-patient telemetry use within the MEMO Cue system; 12g weight, up to 8-day battery life, stable Bluetooth data transmission with disconnection alerts, defibrillation protection, and a user-friendly design that has won a Design Award. Designed for hospital in-patients requiring continuous cardiac and respiratory monitoring.

4MEMO Patch 2
CategoryWearable ECG sensor
Description

Second-generation wearable ECG monitor for ambulatory monitoring within the MEMO Care solution; all-in-one integrated design with a 64% weight reduction and 75% volume reduction versus the prior model, IP27 water/dust resistance, and up to 14-day continuous ECG monitoring. Winner of the iF Design Award 2024 (2 categories) and Red Dot Design Award. Designed for ambulatory cardiac patients requiring extended monitoring.

5MEMO Watch
CategoryWearable multi-biosignal device
Description

Wrist-worn wearable multi-biosignal device measuring ECG, blood pressure, and oxygen saturation, developed using non-compressive non-invasive blood pressure estimation technology. Received CE certification in 2021 and was the first domestic wearable ECG device to be listed for Korean health insurance coverage by HIRA. Designed for continuous outpatient multi-parameter vital sign monitoring.

6MEMO Band
CategoryWearable pulse oximeter
Description

Wearable pulse oximeter for oxygen saturation measurement; received MFDS (Korea Ministry of Food and Drug Safety) medical device category approval in May 2025. Designed for patients requiring continuous oxygen saturation monitoring alongside HUINNO's ECG monitoring portfolio.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-30
Description

Huinno partnered with Yuhan USA to enter the US digital healthcare market, focusing on AI-based cardiac monitoring solutions and launching a clinical prediction platform. The collaboration aims to develop sales, marketing, regulatory support, and logistics to accelerate market entry.

2Bucheon Sejong Hospital (부천세종병원)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

MOU signed for ECG analysis collaboration in February 2023 for research and clinical applications.

huinno.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

MOU signed for data-based arrhythmia diagnosis and treatment technology collaboration in August 2022. Initial MOU for arrhythmia diagnosis and treatment technology was signed in April 2021.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Joint venture company established in 2022 with KUMC Healthcare Technology Holdings (고려대학교 의료기술지주) for healthcare technology development and commercialization.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-01
Description

Yuhan Corporation holds domestic Korean distribution rights for MEMO Patch under licensing agreement signed June 2022. Yuhan also provided strategic investment of 50 billion KRW in 2020 and is a key investor.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform directly compete with Huinno's MEMO Patch 2 / MEMO Care solution; both target the same cardiology workflow of extended-duration patch monitoring replacing traditional Holter.

TypeDirect peer
Description

Masimo's Patient SafetyNet and rainbow SET pulse oximetry / continuous monitoring platform competes directly with Huinno's MEMO Cue + MEMO Band combination for multi-parameter bedside and ambulatory monitoring in hospital general wards.

TypeEmerging player
Description

SmartCardia's AI-driven wearable patch for continuous ECG and vital signs monitoring is a direct emerging competitor to Huinno's MEMO Patch M, focused on similar in-patient and remote monitoring use cases.

TypeDirect peer
Description

AliveCor's KardiaMobile 6L and KardiaNet AI ECG service compete in consumer and clinical-grade AI ECG interpretation — closely paralleling Huinno's MEMO Watch and MEMO AI ECG classification offering.

TypeBroad incumbent
Description

GE HealthCare's patient monitoring portfolio (incl. EK-Pro, ApexPro) competes with MEMO Cue in-hospital telemetry; ICU and general-ward cardiac monitoring is a core GE franchise, making it the most established incumbent Huinno must displace.

TypeRegional player
Description

Wellysis is a Korean digital health company with FDA-cleared S-Patch ECG wearable and AI arrhythmia analysis — a domestic Korean peer to Huinno with overlapping product positioning and similar regulatory strategy targeting the US market.

TypeBroad incumbent
Description

Boston Scientific acquired Preventice Solutions whose BodyGuardian Heart remote cardiac monitor competes with Huinno's MEMO Patch in ambulatory arrhythmia detection; large medtech with global sales infrastructure.

TypeEmerging player
Description

Vivalink provides wearable ECG and remote patient monitoring platform technology that overlaps with Huinno's MEMO ecosystem; focuses on ambulatory cardiac and RPM data infrastructure.

TypeBroad incumbent
Description

Philips acquired BioTelemetry to offer MCOT ambulatory ECG and IntelliVue in-hospital patient monitoring — overlapping with Huinno's MEMO Care (ambulatory) and MEMO Cue (in-patient telemetry) product lines but as part of a much larger portfolio.

TypeBroad incumbent
Description

Hillrom (now part of Baxter) provides in-hospital vital signs and cardiac monitoring solutions that overlap with MEMO Cue; broad incumbent with established hospital purchasing relationships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HUINNO

Cardiac Monitoring Solutionshuinno.com

HUINNO is a South Korea-based digital health company that combines FDA-cleared wearable ECG devices with AI-based arrhythmia detection algorithms to deliver continuous cardiac monitoring for hospitals and cardiology departments, serving both in-patient telemetry and ambulatory monitoring use cases.

What HUINNO does

HUINNO is a South Korea-based digital health company founded in 2014 that combines FDA-cleared wearable biosignal monitoring hardware with proprietary AI-based analytics to enable continuous cardiac monitoring and arrhythmia detection in both hospital and ambulatory settings. Its core platform comprises MEMO Cue, an in-hospital telemetry solution supporting up to 300 simultaneous patients via web-based monitoring on Cloud or On-Premise deployments, and MEMO Care, an ambulatory ECG monitoring solution extending continuous monitoring up to 14 days versus the standard 24-48 hour Holter window. Supporting hardware includes MEMO Patch M (FDA 510(k)-cleared, 12g, 8-day battery, defibrillation-protected), MEMO Patch 2 (IP27-rated, 14-day monitoring, iF and Red Dot Design Award winner), MEMO Band (MFDS-approved pulse oximeter), and MEMO Watch (CE-certified wrist-type multi-biosignal device). The proprietary MEMO AI engine powers bit-level deep-learning ECG segmentation and arrhythmia classification, ranked 1st globally in 4-lead and 6-lead categories at the PhysioNet AI Challenge 2021 and clinically validated at major Korean university hospitals with an 89% improvement in arrhythmia detection vs. traditional Holter monitoring.

The company operates a hybrid revenue model spanning hardware sales of wearable ECG devices to hospitals, SaaS subscriptions for MEMO Cue and MEMO Care monitoring platforms, and licensing/distribution arrangements including domestic Korean rights held by Yuhan Corporation and US market entry via Yuhan USA (announced March 2026). The recent acquisition of Korean National Health Insurance reimbursement code EX871 (March 2025) for remote heartbeat monitoring marks a transition toward recurring reimbursement-based revenue. HUINNO serves hospitals and cardiology departments as primary customers (H Plus Yangji Hospital being the first commercial MEMO Cue deployment covering ~100 beds), with secondary expansion targets including the US healthcare market and broader patient monitoring applications in general wards beyond ICU. The company has raised approximately $60M+ cumulatively across multiple funding rounds from 2019-2022, is backed by strategic investor Yuhan Corporation alongside financial investors including Smilegate Investment, Woori Venture Partners, and FuturePlay, and operates a subsidiary structure including wholly-owned Huinno AIM and the KHAIM joint venture with Korea University Medical Technology Holdings.

HUINNO firmographics

Firmographics
Name
HUINNO
Legal name
주식회사 휴이노 (Huinno Co., Ltd.)
Website
https://huinno.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
HUINNO is a South Korea-based digital health company that combines FDA-cleared wearable ECG devices with AI-based arrhythmia detection algorithms to deliver continuous cardiac monitoring for hospitals and cardiology departments, serving both in-patient telemetry and ambulatory monitoring use cases.
Ownership category
akta.pro rank

HUINNO industry classification

Industry
Product category
Cardiac Monitoring Solutions
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAQAF
Pulse Oximeters & Respiratory Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Cardiac monitoring software
  • Wearable ECG devices
  • Arrhythmia detection AI
  • Remote patient monitoring
  • Digital health platform

Where HUINNO is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

HUINNO business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Wearable Medical Device Sales: Sales of wearable ECG monitoring devices including MEMO Patch M, MEMO Patch 2, and MEMO Watch. Devices are sold to hospitals and healthcare providers for patient monitoring.
  2. Software as a Service (SaaS) - Remote Patient Monitoring: Cloud-based software subscriptions for MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring) platforms. The company received insurance reimbursement codes (보험수가) for remote heartbeat monitoring technology (EX871) in March 2025.
  3. Licensing and Distribution Agreements: Licensing agreements for MEMO Patch domestic rights (Yuhan Corporation) and potential international distribution partnerships.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

HUINNO product offering

Product offering

Core offering

HUINNO develops and sells AI-powered cardiac monitoring solutions that combine wearable biosignal sensors with cloud-based AI analytics to enable continuous in-hospital patient monitoring (MEMO Cue) and extended ambulatory ECG monitoring (MEMO Care). The integrated stack includes FDA 510(k)-cleared and CE-certified wearable ECG/respiration devices (MEMO Patch M, MEMO Patch 2, MEMO Watch, MEMO Band), web-based central monitoring and ECG analysis software, and an award-winning arrhythmia detection algorithm, sold primarily to hospitals and cardiology departments.

Product overview

HUINNO offers a dual-core product architecture centered on MEMO Cue (in-patient telemetry) and MEMO Care (ambulatory ECG monitoring), both powered by proprietary MEMO AI technology. The portfolio comprises two wearable ECG devices (MEMO Patch M for hospital monitoring, MEMO Patch 2 for extended ambulatory monitoring), supporting software platforms (MEMO Care Web for patient management, MEMO Report for ECG analysis, Medical Staff App for device control, MEMO for Desktop for data management), and mobile/portable solutions (MEMO Cue Mobile for hospital-wide monitoring). Recent additions include MEMO Band for oxygen saturation and MEMO Watch for multi-parameter vital signs. The system integrates with Samsung Galaxy devices and KakaoTalk chatbot for patient symptom tracking.

Differentiator

Problem solved

Functional benefit

Brands

  • MEMO: Digital health platform brand featuring products including MEMO Patch (wearable ECG monitoring device) and MEMO Care solutions.

Products and services

  • MEMO Cue In-hospital patient telemetry solution combining wearable ECG/respiration sensors (MEMO Patch M) with a web-based central monitoring software (MEMO Cue) and portable data transmission device (MEMO Cue Mobile), enabling 24-hour continuous cardiac monitoring beyond the ICU into general wards, multi-patient monitoring of up to 300 patients simultaneously, AI-based arrhythmia detection with 19 vital sign and 8 technical alarms, and Cloud or On-Premise deployment. Targeted at hospitals and healthcare systems for continuous inpatient cardiac monitoring.
  • MEMO Care Ambulatory ECG monitoring solution using wearable devices (MEMO Patch 2) and big-data AI analysis to extend monitoring periods up to 14 days versus the 48-hour limit of standard Holter tests. Includes a web-based patient management system, ECG analysis and editing, automated report generation, and KakaoTalk chatbot integration for patient symptom and sleep logging. Targeted at cardiology departments and arrhythmia clinics for ambulatory arrhythmia diagnosis.
  • MEMO Patch M Wearable ECG and respiration monitor for in-patient telemetry use within the MEMO Cue system; 12g weight, up to 8-day battery life, stable Bluetooth data transmission with disconnection alerts, defibrillation protection, and a user-friendly design that has won a Design Award. Designed for hospital in-patients requiring continuous cardiac and respiratory monitoring.
  • MEMO Patch 2 Second-generation wearable ECG monitor for ambulatory monitoring within the MEMO Care solution; all-in-one integrated design with a 64% weight reduction and 75% volume reduction versus the prior model, IP27 water/dust resistance, and up to 14-day continuous ECG monitoring. Winner of the iF Design Award 2024 (2 categories) and Red Dot Design Award. Designed for ambulatory cardiac patients requiring extended monitoring.
  • MEMO Watch Wrist-worn wearable multi-biosignal device measuring ECG, blood pressure, and oxygen saturation, developed using non-compressive non-invasive blood pressure estimation technology. Received CE certification in 2021 and was the first domestic wearable ECG device to be listed for Korean health insurance coverage by HIRA. Designed for continuous outpatient multi-parameter vital sign monitoring.
  • MEMO Band Wearable pulse oximeter for oxygen saturation measurement; received MFDS (Korea Ministry of Food and Drug Safety) medical device category approval in May 2025. Designed for patients requiring continuous oxygen saturation monitoring alongside HUINNO's ECG monitoring portfolio.

Quantifiable outcome

  • 89% higher arrhythmia detection rate compared to traditional 24-hour Holter monitoring
  • +4 more outcomes

Companies that use HUINNO

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

HUINNO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature8 records

HUINNO partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Yuhan USAcoreChannel Partner/ Reseller/ Distributor · 30 March 2026Huinno partnered with Yuhan USA to enter the US digital healthcare market, focusing on AI-based cardiac monitoring solutions and launching a clinical prediction platform. The collaboration aims to develop sales, marketing, regulatory support, and logistics to accelerate market entry.
  • Bucheon Sejong Hospital (부천세종병원)minorStrategic or Co-development Partner · 1 February 2023MOU signed for ECG analysis collaboration in February 2023 for research and clinical applications.
  • Johnson & Johnson Medical Korea (한국존슨앤드존슨메디칼)coreStrategic or Co-development Partner · 1 August 2022MOU signed for data-based arrhythmia diagnosis and treatment technology collaboration in August 2022. Initial MOU for arrhythmia diagnosis and treatment technology was signed in April 2021.
  • KHAIM (주)카임)coreStrategic or Co-development Partner · 1 August 2022Joint venture company established in 2022 with KUMC Healthcare Technology Holdings (고려대학교 의료기술지주) for healthcare technology development and commercialization.
  • Yuhan Corporation (유한양행)coreChannel Partner/ Reseller/ Distributor · 1 June 2022Yuhan Corporation holds domestic Korean distribution rights for MEMO Patch under licensing agreement signed June 2022. Yuhan also provided strategic investment of 50 billion KRW in 2020 and is a key investor.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

HUINNO competitors and assessment

Company assessment

Direct peers

  • iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform directly compete with Huinno's MEMO Patch 2 / MEMO Care solution; both target the same cardiology workflow of extended-duration patch monitoring replacing traditional Holter.
  • Masimo: Masimo's Patient SafetyNet and rainbow SET pulse oximetry / continuous monitoring platform competes directly with Huinno's MEMO Cue + MEMO Band combination for multi-parameter bedside and ambulatory monitoring in hospital general wards.
  • AliveCor: AliveCor's KardiaMobile 6L and KardiaNet AI ECG service compete in consumer and clinical-grade AI ECG interpretation — closely paralleling Huinno's MEMO Watch and MEMO AI ECG classification offering.

Emerging players

  • SmartCardia: SmartCardia's AI-driven wearable patch for continuous ECG and vital signs monitoring is a direct emerging competitor to Huinno's MEMO Patch M, focused on similar in-patient and remote monitoring use cases.
  • Vivalink: Vivalink provides wearable ECG and remote patient monitoring platform technology that overlaps with Huinno's MEMO ecosystem; focuses on ambulatory cardiac and RPM data infrastructure.

Broad incumbents

  • GE HealthCare: GE HealthCare's patient monitoring portfolio (incl. EK-Pro, ApexPro) competes with MEMO Cue in-hospital telemetry; ICU and general-ward cardiac monitoring is a core GE franchise, making it the most established incumbent Huinno must displace.
  • Boston Scientific (Preventice BodyGuardian): Boston Scientific acquired Preventice Solutions whose BodyGuardian Heart remote cardiac monitor competes with Huinno's MEMO Patch in ambulatory arrhythmia detection; large medtech with global sales infrastructure.
  • Philips (BioTelemetry / Cardiac Monitoring): Philips acquired BioTelemetry to offer MCOT ambulatory ECG and IntelliVue in-hospital patient monitoring — overlapping with Huinno's MEMO Care (ambulatory) and MEMO Cue (in-patient telemetry) product lines but as part of a much larger portfolio.
  • Hillrom / Baxter (Welch Allyn, Cardio Express): Hillrom (now part of Baxter) provides in-hospital vital signs and cardiac monitoring solutions that overlap with MEMO Cue; broad incumbent with established hospital purchasing relationships.

Regional players

  • Wellysis: Wellysis is a Korean digital health company with FDA-cleared S-Patch ECG wearable and AI arrhythmia analysis — a domestic Korean peer to Huinno with overlapping product positioning and similar regulatory strategy targeting the US market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

HUINNO social profiles

Digital presence

HUINNO compliance and trust

Trust signal

Compliance3 records

HUINNO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HUINNO leadership team

Management profile

Number of profiles

Profiles7 records

HUINNO subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

HUINNO funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HUINNO M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HUINNO

What does HUINNO do?

HUINNO develops and sells AI-powered cardiac monitoring solutions that combine wearable biosignal sensors with cloud-based AI analytics to enable continuous in-hospital patient monitoring (MEMO Cue) and extended ambulatory ECG monitoring (MEMO Care). The integrated stack includes FDA 510(k)-cleared and CE-certified wearable ECG/respiration devices (MEMO Patch M, MEMO Patch 2, MEMO Watch, MEMO Band), web-based central monitoring and ECG analysis software, and an award-winning arrhythmia detection algorithm, sold primarily to hospitals and cardiology departments.

Is HUINNO a public or private company?

HUINNO is a private company. It is classified as venture growth investor backed and is currently operating.

When was HUINNO founded?

HUINNO was founded in 2014. It employs 51 to 100 people.

Where is HUINNO based?

HUINNO is headquartered in Seoul, South Korea, in the Asia region.

How does HUINNO make money?

Three revenue lines are on record. Wearable Medical Device Sales are the primary driver. The others are software as a Service (SaaS) - Remote Patient Monitoring and licensing and Distribution Agreements.

Who are HUINNO's main competitors?

Direct peers on record are iRhythm Technologies, Masimo and AliveCor. Emerging players are SmartCardia and Vivalink. Broad incumbents are GE HealthCare, Boston Scientific (Preventice BodyGuardian), Philips (BioTelemetry / Cardiac Monitoring) and Hillrom / Baxter (Welch Allyn, Cardio Express). Wellysis is listed as a regional player.

Does HUINNO have an API?

No public API is recorded for HUINNO.

What industry is HUINNO in?

HUINNO's product category is Cardiac Monitoring Solutions. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NateHuinno, passing the evaluation, a 'green light' for entering KOSDAQ... A bold move in AI heart monitoring: Nate NewsHuinno passed the technical evaluation for a KOSDAQ special listing, receiving A and BBB ratings from two agencies. The company will proceed with a preliminary listing review after consultations. It plans to expand its AI-based patient monitoring products, including a clinical decision support system.VenturesquareHuinno, preparing for IPO in earnest... Strengthening the growth foundation through management and board restructuring.Huino, a digital healthcare company, is reorganizing its management and board ahead of its IPO and global expansion. It appointed Park Moon-kyu as CFO, Ryu Ho-geol as CMO, and outside directors Choi Jae-won and Sang Du-hwan. The company aims to strengthen capital market readiness and global business capabilities.The Korea HeraldHuinno launches first commercial rollout of AI telemetry systemHuinno, a South Korean digital health company, has launched the first commercial deployment of its AI-based telemetry system Memo Cue at H Plus Yangji Hospital, covering approximately 100 beds for continuous cardiac monitoring. The system, which includes the FDA 510(k)-cleared Memo Patch M wearable ECG device, analyzes ECG data in real time to enable early detection of abnormalities and extends monitoring beyond intensive care units into general wards. Huinno plans to expand adoption across major hospitals through its partnership with Yuhan Corporation.The Korea HeraldHuinno partners Yuhan USA to enter US digital health care marketHuinno, an AI-based cardiac monitoring startup, has signed a strategic partnership with Yuhan USA Corporation to expand its ECG monitoring solutions into the US digital healthcare market. The partnership covers sales channel development, localized marketing, regulatory approval support, and logistics operations for Huinno's product lineup including MEMO Patch M, MEMO Cue, MEMO Care, and the clinical prediction platform Vital-PICASO. The collaboration combines Huinno's AI-driven monitoring technologies with Yuhan USA's local commercialization capabilities to accelerate adoption within the US healthcare system.TracxnTop Companies in Wearable ECG Patch (Oct, 2025)The article presents a list of top startups in the wearable ECG patch sector, highlighting iRhythm Tech, Vital Connect, Huinno, and B-Secur as key players. It provides specific details on their founding years, locations, funding stages, and total capital raised to date. The report also notes that many of these companies were founded by alumni from prestigious institutions like Carnegie Mellon University and Stanford University.Startuprecipe[StartupRecipe] 5 rising Korean alternative food startupsSeveral Korean startups raised significant funding in recent days, including Watcha which secured KRW 36 billion in a Series D funding round, and Huinno that raised KRW 20 billion in a Series B round. The move reflects growing investor interest in the startup ecosystem, particularly in alternative food and digital healthcare sectors, which is expected to expand in the coming years. Notably, the alternative foods market is anticipated to reach a market size of $140 billion by 2029.The Korea Herald[News Focus] As 'remote' gains momentum, how will medical system change?The COVID-19 pandemic has accelerated the adoption of telemedicine infrastructure in South Korea, driving regulatory sandbox initiatives for companies like Huinno despite strong opposition from medical professional associations. While global wearable device spending is projected to reach $52 billion in 2020 with major contributions from Apple and Samsung, Korean regulations currently restrict foreign tech giants like Apple and Philips from offering medical-grade ECG functions.Inc.22 Korean Startups to Watch For in 2015The article profiles 22 Korean startups to watch in 2015, including NPCore's security engine, HUiNNO's wearable health device, BLUEPIN's kids education app, and Siliconarts' VR hardware. It notes Google's planned 20,000-sq.-ft. Seoul start-up center and government programs supporting global ambitions.